Rubella seroprevalence among women of childbearing age residing in a rural region: is there a need for rubella vaccination in Turkey?
It is essential to evaluate the susceptibility of women in the reproductive age group to rubella virus in order to set strategies for the prevention of congenital rubella syndrome (CRS). Turkey began implementing measles-mumps-rubella vaccination as part of the national vaccination schedule for children (12 months, 6 years) and adolescents (14 years) in July, 2006, and there is an ongoing discussion of the need for a policy of vaccinating women of child-bearing age against rubella. The aim of this study was to determine the rubella seroprevalence among women in the reproductive age group in a rural district in Ankara and to provide data about rubella susceptibility for policymakers. Four hundred ninety of the women in the 15- to 49-year-old age group in the region who were targeted were reached (68.2%), and 467 (65.0%) of them who had a convenient serology were included in the study. Rubella IgG antibodies were quantified by the enzyme-linked immunosorbent assay method. Seropositivity was 95.5% for the total group and 96.2% among pregnant women. The seropositivity of this rural group of women was found to be high, but in order to rule out the need for a rubella vaccination program for women of child-bearing age, large-scale studies in different settings and studies that describe the CRS burden in Turkey are required.
Aksakal
F Nur
FN
Department of Public Health, Gazi University Faculty of Medicine, Ankara, Turkey. naksakal@gazi.edu.tr.
Maral
Isil
I
Cirak
Meltem Yalinay
MY
Aygun
Remzi
R
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008875:Middle Aged; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D012409:Rubella / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D012411:Rubella Vaccine / Q000008:administration & dosage*; D012412:Rubella virus / Q000276:immunology; D012424:Rural Population; D016036:Seroepidemiologic Studies; D014421:Turkey / Q000453:epidemiology
D007074:Immunoglobulin G; D012411:Rubella Vaccine